Contineum Therapeutics, Inc. (CTNM)
Nasdaq: CTNM · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2023
Who owns Contineum Therapeutics, Inc.
As filed with the SECHolders of 5% or more
5
Janus Henderson Group PLC holds 7.9% of Class A Common Stock, as its SCHEDULE 13G filed Feb 17, 2026 says.
Directors and officers
12
report now, of 13 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Janus Henderson Group PLC
SCHEDULE 13G · filed Feb 17, 2026 · Class A Common Stock
Balyasny Asset Management L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Class A Common Stock · 7.4% in May 15, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Jul 27, 2026 · Class A Stock
Franklin Resources, Inc.
SCHEDULE 13G/A · filed Jan 29, 2026 · Class A Common Stock, $0.001 par value per share · 7.7% in Nov 4, 2025
Trails Edge Capital Partners, LP
SCHEDULE 13G · filed Oct 22, 2026 · Class A Common Stock, $0.001 par value per share
Jerome G. Pfund
SCHEDULE 13G/A · filed Feb 14, 2025 · Class A Common Stock · reported falling below 5%
RA Capital Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Class A Common Stock, $0.001 par value per share · reported falling below 5%, from 7.2% in Feb 17, 2026
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Class A Common Stock, par value $0.001 per share · reported falling below 5%, from 7.5% in May 15, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed Jul 17, 2026 · Class A Common Stock, par value $0.001 per share · reported falling below 5%, from 5.1% in Apr 17, 2026
What CTNM reports owning in othersstakes of 5% or more, and other ties
Contineum Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
31sales
0purchases
31sales on a scheduled plan
3people selling
$1.9Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 24 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Lorrain Daniel S. | Chief Scientific Officer | 19 | $1.1M | 19 | 0 | $0 |
| Stengone Carmine N. | CEO and President | 7 | $400,000 | 7 | 0 | $0 |
| Watkins Tim | CMO & Head of Development | 5 | $300,000 | 5 | 0 | $0 |